Author(s):
Kajal Vable Deshmukh, Priti Kale, Madhuri Deshmukh, Minal Ghante
Email(s):
vablekajal@gmail.com
DOI:
10.52711/2231-5675.2026.00017 
Address:
Kajal Vable Deshmukh*, Priti Kale, Madhuri Deshmukh, Minal Ghante
Department of Pharmaceutical Quality Assurance, Smt. Kashibai Navale College of Pharmacy, Sinhgad Institute of Pharmacy, Kondhwa, Savitribai Phule, Pune University.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2026
ABSTRACT:
The goal of this study was to use high-performance liquid chromatography with an Analytical Quality by Design (AQbD). The experiment was performed on a Methanol: Water HPLC system equipped with a Raptor C-18 column. To achieve chromatographic separation, a mobile phase of Triethylamine buffer (0.05%; pH 3.0) and Ortho Phosphoric acid in an 80:20 v/v ratio was used with a flow rate of 0.7mL/min for 10 minutes at 235 nm. AQbD was used to optimize chromatographic conditions using a central composite design (CCD). A factorial design of 17 (three factors and three responses) was used with StatEase Inc.'s Design Expert 10.0.1 software. The HPLC method was validated using ICH, and it met all acceptance criteria. In the dilution range of 10to60µg/mL, the procedure was shown to be linear. HPLC method development and validation for tablet dosage form qualitative determination of antidepressants and antipsychotic drugs in a respective manner.
Cite this article:
Kajal Vable Deshmukh, Priti Kale, Madhuri Deshmukh, Minal Ghante. Central Composite Design Aided Method Development and Validation of a Reverse Phase HPLC Method for Escitalopram in Synthetic Mixture. Asian Journal of Pharmaceutical Analysis. 2026; 16(2):114-8. doi: 10.52711/2231-5675.2026.00017
Cite(Electronic):
Kajal Vable Deshmukh, Priti Kale, Madhuri Deshmukh, Minal Ghante. Central Composite Design Aided Method Development and Validation of a Reverse Phase HPLC Method for Escitalopram in Synthetic Mixture. Asian Journal of Pharmaceutical Analysis. 2026; 16(2):114-8. doi: 10.52711/2231-5675.2026.00017 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2026-16-2-7
REFERENCES:
1. Taylor AB, Gabriel T, Donna MP, Evian G, John AR, Anthony WF, et al.” Antidepressant side effects and their impact on treatment outcomes in people with major depressive disorder: an Ispot-d report. Translation Psychiatry” 2021;11:417. https://doi.org/10.1038/s41398-021-01533-1
2. Moret C, Isaac M, Briley M. et al., “Problems associated with long-term treatment with selective serotonin reuptake inhibitors” Journal of Psychopharmacology. 2009;23:967–74. https://doi.org/10.1177/0269881108093582
3. Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-Møller K, et al. “Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis” BMC Psychiatry. 2017;7:58. https://doi.org/10.1186/s12888-016-1173-2
4. Saveanu R, Etkin A, Duchemin AM, Goldstein-Piekarski A, Gyurak A, Debattista C, et al.,” The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment” J Psychiatr Res. 2015;61:1–12. https://doi.org/10.1016/j.jpsychires.2014.12.018
5. URL Escitalopram | C20H21FN2O | CID 146570 - PubChem
6. Bhumika D. Sakhreliya*, Dr. Priti D. Trivedi, Darshana K. Modi, et al., “Development and Validation of Spectrophotometric Methods for Simultaneous Estimation of Escitalopram oxalate and Etizolam in their Combined Tablet Dosage Form” Journal of Pharmaceutical Science and Bioscientific Research. 2012; 2: 5.
7. Suneetha A., Syama Sundar B. A Validated UV Spectrophotometric Method for Estimation of Escitalopram Oxalate in Bulk and Pharmaceutical Dosage Forms. Asian J. Research Chem. 3(4): Oct. - Dec. 2010; Page 935-937.
8. Sharma S, Rajpurohit H, Sonwal C, Bhandari A, Choudhary V, Jain T. Zero-order spectrophotometric method for estimation of escitalopram oxalate in tablet formulations. J Young Pharm. 2010 Oct;2(4):420-3. doi: 10.4103/0975-1483.71626. PMID: 21264107; PMCID: PMC3019386.
9. Khedkar S, Dalvi R, Undre D, Khaladkar V, et al., “A Review Paper: Method Development and Validation of Escitalopram” International Journal of Pharmaceutical Research and Applications. 2025;10:2: 575-578. 10.35629/4494-1002575578
10. Srivastav A, Srinivasulu N, Nahar A, Hafeez Pasha Qhadri S, Yegnoor A, et al., “Spectroscopic Method For Quantification of Escitalopram Oxalate In Bulk And Tablet Dosage Form” International Journal of Novel Research and Development. 2022; 7:11.